Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Good financial results growth rate 44.3% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-0.9%)
  • Dividend yield for the last twelve months 5.3%
  • Free cash flow yield 8.8% (LTM)
  • Share price is 17.6% higher than minimum and 42.5% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (16.4x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (-4.1%)46.65
year average price 51.29  


year start price 56.22 2024-11-16

max close price 63.11 2025-03-10

min close price 42.60 2025-10-29

current price 46.65 2025-11-15
Common stocks: 2 111 517 922

Dividend Yield:  5.3%
FCF Yield LTM: 8.8%
EV / LTM EBITDA: 16.4x
EV / EBITDA annualized: 10.6x
Last revenue growth (y/y):  +2.8%
Last growth of EBITDA (y/y):  +85.8%
Historical revenue growth:  +1.0%
Historical growth of EBITDA:  -2.8%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 98 502
Net Debt ($m): 33 300
EV (Enterprise Value): 131 802
EBITDA LTM ($m): 8 033
EV / LTM EBITDA: 16.4x
Price to Book: 5.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-11-13zacks.com

BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?

2025-11-13zacks.com

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

2025-11-12fool.com

3 Healthcare Stocks Topping a 2025 List of Dividend Yields

2025-11-06247wallst.com

5 High-Yield Blue-Chip Dividend Giants Set to Soar If Rates Fall to 3%

2025-11-03businesswire.com

Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes

2025-10-31youtube.com

Final Trades: Rocket Companies, Meta, Cleveland-Cliffs, Bristol Myers

2025-10-30zacks.com

BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View

2025-10-30barrons.com

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.

2025-10-30wsj.com

Bristol Myers Squibb Profit Soars, Raises Revenue Guidance

2025-10-27zacks.com

Ahead of Bristol Myers (BMY) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data